A gene therapy being developed by Lexeo Therapeutics to treat cardiomyopathy caused by Friedreich ataxia, a rare neurodegenerative genetic disease, has achieved good interim results in a phase 1/2 trial.
A Series A financing round, led by Deerfield Management, is aimed at accelerating a new cell therapy modality for the treatment of neurological disorders, including Parkinson’s Disease.